Loading...
Header Logo
Keywords
Last Name
Institution

JIANJUN ZHANG

TitleAssistant Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90. PMID: 25590605.
      View in: PubMed
    2. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. PMID: 25301631.
      View in: PubMed
    3. Zhang J, Gold KA, Kim E. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs. 2012 Sep; 21(9):1417-26. PMID: 22725255.
      View in: PubMed
    4. Erratum. Nature Medicine. 12:253.
    5. Erratum. Nature Medicine. 12:149.
    6. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clinical Cancer Research. 22:6278-6289.
    7. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    8. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery. 5:861-878.
    9. Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications. 7.
    10. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clinical Lung Cancer.
    11. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer.
    12. Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib. Cancer Treatment Communications. 4:34-36.
    13. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. Cancer Biology and Therapy. 7:1492-1497.
    ZHANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description